The impact of the geopolitical disruption is starting to tell on global supply chains for medicines and key chemicals for the pharmaceutical industry.
Shah Capital has fired another broadside at vaccine firm Novavax, accusing its board and management of a "destruction in shareholder value."
Neurocrine Biosciences has agreed a $2.9bn deal to buy Soleno Therapeutics and its treatment for a rare, genetic form of severe obesity.
Trump signs his pharma tariffs executive order, which won't affect most large pharma groups but could deal a hefty blow to smaller companies.
In Philadelphia last month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Editor's Picks
